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Abstract: 
The main objective of my project is to determine the bacterial cell wall intermediates in E.coli 
and develop an LCMS method that Phosphomycin is a PEP analogue that irreversibly inhibits 
UDP-GluNAc-enolpyruvate transferase (MurA enzyme), which prevents the formation of N-
acetyl muramic acid, which is an essential element in the Peptidoglycan cell wall. Antibacterial 
agents have a tremendous impact on human health. Most of the antibacterial agents, including 
beta lactams target the bacterial cell wall biosynthesis.1 The pathway for Escherichia coli is 
shown in page 19. Among the most widely used antibiotics, beta lactams inhibit the penicillin 
binding protein (PBPs) 1 which block the cross linking reactions of cell wall biosynthesis. A 
Liquid chromatography-tandem mass spectrometry provides a new technology to detect and 
quantitation of cell wall intermediates. 
 
Introduction 
Tandem mass spectrometry (MS/MS) coupled with HPLC (high pressure liquid chromatography) 
is the analytical technique of choice for most assays used during new drug discovery. Some 
applications are:  
• Biotechnology: Mainly used in analysis of proteins, peptides, oligonucleotides  
• Pharmaceutical: Mainly used in drug discovery, pharmacokinetics, drug metabolism  
• Clinical Biochemistry and Toxicology: neonatal screening, haemoglobin analysis, drug 
testing.  
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MS/MS used with or without chromatographic separation offers the advantage of 1) analytical 
sensitivity and 2) selectivity for drug and drug metabolite analysis. These advantages are 
achieved through reduction in interferences from other sample components. This allows the 
development of analytical methods for complex mixtures that are fast, require less stringent 
sample preparation, less chromatographic separation and therefore consumes much less solvent, 
allowing higher sample throughput. Single stage mass spectrometry measures the molecular 
mass of a compound and/or its fragments. MS/MS consists of two or more mass spectrometer 
analyzers all in a single instrument. More popular tandem mass spectrometers include those of 
the quadrupole-quadrupole type (also known as Triple Quadrupole instruments), or the hybrid 
types: including magnetic sector/quadrupole, and more recently, the quadrupole/time-of-flight 
(Q-TOF) geometries.  
Tandem mass spectrometer consists of mainly 3 parts: 
 1) Ionization source,  
2) Analyzer  
3) Detector. 
A sample introduced into the ionization source becomes ionized. This makes the sample 
components easier to manipulate. The ions are removed into the analyzer where they are 
separated according to their mass -to-charge ratios (m/z). The separated ions are then 
fragmented. The fragments are detected and the signal created by the detected fragment ions is 
sent to a data system where the m/z ratios are stored together with their relative abundance.15  
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Hybrid triple quadrupole/Linear Ion Trap technology provides high sensitivity. By using this 
quadrupole scanning functionality with sensitive linear ion trap scans we can reduce the analysis 
time and get more information for every experiment. This linear ion Trap technology of 3200 Q 
TRAP system is used to identify and quantify components from complex samples in a single 
run.We need some specification to run this 3200 Q TRAP LCMS software on a personal 
computer. We have to maintain the Mass range m/z 5-1,700 in quad mode 50-1,700 in linear ion 
trap mode. Scan speed is upto2400 amu/sec in quad mode and upto4000 amu/sec in linear ion 
trap mode 16. This instrument contains different types of scan modes which are traditionally not 
available in a single detector. These modes allow quantification, confirmation and identification 
with a single detector. The most common detectors used are photomultiplier, the electron 
multiplier and the micro-channel plate detectors. 
Materials: 
Chemicals: 
E.coli, UDP-Glucose, UDP-N acetyl glucose, Solvent A, Solvent B, Solvent C, Ion pair reagent, 
Acetone, water, Liquid nitrogen, LB Broth media. 
          Solvent A: water +0.1N HCOOH 
          Solvent B: 70% C + 30% A. 
          Solvent C: Aceto nitrile + 0.1N HCOOH. 
          Ion pair reagent: Dimethyl Hexyl Amine 160 mM PH at 3. 
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Instruments: 3200 Q TRAP ION CHARGE LCMS, RT 6000 Refrigerated Centrifuge. 
Methodology: 
Scan types: Multiple reactions monitoring (MRM)  
Enhanced Product Ion scans. (EPI) 
Precursor Ion scans. (PI) 
MRM METHOD: 
Multiple Reaction monitoring (MRM):  It Involves both analyzers such that only ions of 
selected molecular weight are allowed to pass through the first analyzer and only specifically 
selected fragments arising from these are measured by the second analyzer. When a sample is 
introduced into Q1 it passes into Q2 there it undergoes cell collision and fragmentation takes 
place and these fragments are analyzed by the Q3. This method is widely used in drug testing in 
blood and urine samples. It is also very sensitive and specific. 
 
  
Q1= Parent mass of the compound. 
          Q2= Cell collision takes place and fragmentation takes place. 
         Q3= Scan the fragment mass. 
Q1 Q2 Q3 
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        Enhanced Product ion scan: Here we scan the product ions in Q3 (MS2), where as the mass in Q1 
           (MS1) is static. So we should know the compound mass. 
Precursor Ion scan: Here we scan the precursors in Q1 (MS1), where as the mass in Q3 (MS2) is 
static. So we need to know the fragment mass of the compound. 
In general we use MRM method. 
 Before using this instrument we need to know some parameters involved in Quadrupole mode. 
Declustering potential (DP) 
Entrance potential (EP) 
Collision Cell Entrance Potential (CEP) 
Growth and preparation of bacterial extracts:   
 A saturated culture of E.coli was grown in an incubator shaker overnight at 37C. This culture 
was placed in a rotary shaker and incubated with good agitation at 37C. When the culture 
reached OD value to 0.8 at 600nm, a 1/3rd ml portion of culture was placed into sterilized 250 
ml flask.1 from figure 9 flask on left contains sterile medium and flask on right contains medium 
inoculated with E. coli bacteria the day before. The turbidity in second flask due to bacterial 
cells.16 
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 Procedure:
 
 
To identify the intermediates of the cell pathway of E.coli, we use E.coli bacterial extract. Here 
we are using an ion pair reagent (n, n dimethyl hexylamine) 15 because UDP has high negative 
charges in the structure. This ion pair reagent has positive charges. Because of UDP have high 
negative charge ions we are running in negative mode i.e. polarity is negative. The main use of 
Ion pair reagent is ionic samples form an ion pair with ion pair reagents in the mobile phase to 
become electrically neutral. By using this ion pair reagent we can enhance peak shape and 
retention time. In this E.coli extract run we have seen only UDP-GluNAc and UDP-MurNAc 
peaks.  Tandem Mass Spectrometry also know as Mass spectrometry, involves multiple steps of 
mass spectrometry selection, with some form of fragmentation occurring between the stages. 
MS Optimization: 
To remove salts prior to MS optimization, a 50ul of sample is taken and loaded into 200mg of 
C18 silica in a 1-ml syringe prepared by first washing with methanol and then equilibrated with 
solvent ‘A’. After some time the resin was washed with solvent ‘B’. We have to wash with 
solvent ‘C’ also in order to elute salts from the sample.1 
Selection of Internal standard: 
 For internal standard, we have to select either 13C or 14C but 14C is a radioactive, we are 
using 13C. 
 
13C UDP-Glucose is not naturally abundant in nature. In nature 12C is 98.8% abundant 
where as 13C is around 1.1%. 
 
13CUDP-Glucose--- internal standard.  
We are using 13CUDP-Glucose as internal standard because UDP-Glucose and 13CUDP-Glucose 
are structurally similar only changing in the molecular weight. Before using the instrument wash 
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every time syringe with methanol and run the blank with methanol to find out that intensity of 
peak is looking better or not. Next in order to calibrate the instrument take the internal standard 
in syringe and run the mass spectrometer to find out it shows 567.302 or not. Because it is a 
stock solution it will show Molecular weight of 567.302 
 Internal standard is a disodium salt when we add ion pair reagent disodium salts is eluted. We 
have to tune the internal standard. By tuning 13CUDP-Glucose peaks were obtained.  
Quantitative optimization by infusion method: 
Infusion is the continuous flow of a sample at low flow rate into the source using a syringe 
pump. Typically flow rates are 5 to 25uL/min. The infusion method is mainly useful for pure 
standard that can be used for tuning process. 
In this we have to tune the sample what we want exactly i.e. 567.302 For this we have to select 
Mass+ syringe type option and we have to run the sample which is 13CUDP-Glucose by taking 
negative polarity. Here fragments also we can analyze. We can select a mass range between 
566.5 to 568.0 and then select finish automatically it shows the molecular weight of 567.302 
 
 
 
Growth and preparation of bacterial extracts for analysis of antibiotic effects: 
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A saturated culture of E.coli was grown in an incubator shaker overnight at 37C. Cells were 
harvested by centrifugation and resuspended to the desired optical density (O.D 0.5 at 600nm). 
This culture was placed in a flask and incubated with good agitation at 37C. when the culture 
reached to O.D =0.5 3/4th of the portions were placed in 250 ml sterilized culture flask. 
Antibiotics   (Ampicilin, cycloserine and phosphomycin) were added to 8x MIC (MIC =8ug/ml 
for Ampicilin and Cycloserine, for phosphomycin MIC=4ug/ml) in individual flask plus control 
flask without antibiotic. We need to choose the antibiotic based on bacteria i.e. E.coli which is 
gram negative bacteria. 
Growth inhibition was observed with in 15min. After 30 min, the cultures were rapidly cooled in 
ice bath, 4 samples of 10ml were taken into each flask to ice-cold 15ml centrifuge tubes, and 
cells were pelleted by centrifuge at 3000rpm for 10 min. cell pellets were treated 80%acetone 
and shake well and again centrifuge for 10min.1 Supernatants were collected in fresh micro 
centrifuge tubes. Samples were taken and run the LCMS. From the figure 10 we can plot a graph 
between time vs optical density for the confirmation of bacterial growth is good or not. The solid 
diamond represents Control, Solid Square represents Cycloserine, solid triangle represents 
Ampicilin and solid x represents Phosphomycin. 
 
 
 
Results and Discussions: 
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Form the Figure 11 we can conclude that, a control sample treated with Ampicilin and 
Cycloserine antibiotics expected to have small effects on UDP-GlcNAc, UDP-MurNAc. The 
results from this experiment are illustrated in figure 11. Phosphomycin is a PEP analogue that 
irreversibly inhibits UDP-GluNAc-enolpyruvate transferase which is also called as (MurA 
enzyme), which prevents the formation of N-acetyl muramic acid, which is an essential element 
in the Peptidoglycan cell wall.  
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Figure 1: 
E.coli Pathway:                               UDP-GlcNAc 
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 Figure 2:  
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Structure of UDP-GlcNAc: 
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Figure 3:  
 
Structure of UDP-GlcNAc-enolpyruvate: 
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Figure 4: 
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 Structure of UDP-MurNac : 
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Figure 5:  
Structure of UDP-MurNac-L-Ala: 
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Figure 6:  
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Structure of UDP-MurNac-L-Ala--D-Glu: 
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Figure 7:  
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Structure of UDP-MurNac-L-Ala- -D-Glu-Meso-diamino-pimelic acid: 
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Figure: 8 
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3200 QTRAP LCMS:   
 
            Figure 9:                     
Sterile medium vs E.coli bacterial medium 
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Table 1: 
O.D. Values for different antibiotic samples: 
Time Control Cycloserine Ampicilin Phosphomycin 
0 0.481    
5 0.495 0.495 0.495 0.495 
10 0.535 0.538 0.53 0.534 
15 0.537 0.553 0.541 0.557 
20 0.582 0.568 0.555 0.576 
25 0.651 0.502 0.573 0.533 
30 0.725 0.488 0.603 0.527 
35 0.757  0.591 0.459 
40 0.796  0.545  
 
 
 
 
 
 
 
Figure 10:  
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E.coli Growth Curve: 
 
 
 
 
 
 
 
 
 
 
Table 2: 
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13C UDP Glucose MS/MS analysis: 
Table 3:UDP Samples with Antibiotics: 
Sample 13C UDP-
Glucose 
567.3/385 
 
UDP-GluNac 
605.8/385 
 
UDP-MurNac 
677.9/385 
 
Control-1 1.36E+06 9.51E+05 9.54E+04 
Control -2(2ndExtraction) 9.14E+05 6.93E+05 6.77E+04 
Phosphomycin 1.40E+05 2.89E+05 3.99E+04 
Ampicillin 3.00E+05 2.52E+05 2.06E+04 
Cycloserine 2.80E+05 1.49E+05 4.01E+04 
 
 figure: 11 
Mass Fragmet 
(amu)        mass 
 
Parameter Current value New value Intensity(cps) 
567.814     138.875 DP -45 -50 85716 
567.814     158.790 EP -10 -11.5 68849 
567.814     240.950 CEP -32.6 -22.0 83906 
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Measured levels of 13C internal standard from E.coli extracts in the absence and presence of 8× 
MIC for Phosphomycin, Ampicilin and Cycloserine. 
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